About
Moleculera Biosciences
Our Mission and Vision
Moleculera Biosciences, Inc., is a precision medicine company founded to transform how medicine is practiced for patients suffering from chronic disorders driven by inflammation and immune dysfunction. We are intently focused on the discovery and development of next-generation technologies for the identification, diagnosis, and treatment of patients suffering from immune-mediated disorders, including chronic neuropsychiatric and cardiovascular disorders, as well as Alzheimer’s disease.
Three Integrated Components
Our unique technology platform consists of three integrated components, each with a separate intrinsic medical value. When combined, they lead to unprecedented discoveries.
Precision
Medicine Panels
The first platform component includes blood-based immune-mediated autoantibody testing panels that utilize novel biological targets to uncover underlying immune dysfunction in patients with specific chronic disorders. These laboratory results assist clinicians in their clinical diagnosis and help direct treatment to the underlying root of the disorder rather than treating only symptoms.
Biobank and Bioinformatics
The second platform component is our expansive biorepository of phenotypically curated specimens, which grows via our laboratory-tested and inform-consented patients. With over 15,000 immune-mediated neuropsychiatric disorder specimens that are clinically annotated with bioinformatics, it drives the development of AI-developed algorithms to predict the most effective treatment and alleviate trial-and-error interventions.
Target Identification Program
The third platform component is our novel biomarker and therapeutic target identification program, which is probed using our expansive biorepository of phenotypically curated specimens to discover new targets for companion diagnostics and novel targets for targeted therapeutic interventions.
Moleculera Biosciences has multiple translational programs in development to address the unmet needs of patients suffering from chronic, immune-mediated disorders, including chronic neuropsychiatric and cardiovascular disorders, as well as Alzheimer’s disease.
Neuropsychiatric
Program
Our signature program is focused on neurologic, psychiatric, and behavioral disorders, which has resulted in the commercialization of our patented 5-test Autoimmune Brain Panel™ (formerly known as the Cunningham Panel™) that identifies serum autoantibodies directed against specific brain receptors in patients with chronic neuropsychiatric disorders. Positive test results indicate an underlying autoimmune etiology for a patient’s neuropsychiatric symptoms and assist in guiding treatment with anti-inflammatory and/or immune-modulatory agents.
More than two decades of basic research have led to the discovery of this technology, and it is exclusively licensed from the University of Oklahoma.
Cardiovascular Disorders and Alzheimer’s Disease Programs
Our cardiovascular research and development have been completed and is being clinically validated and will soon be commercialized with the launch of the Autoimmune Cardiovascular Panel™, which includes a 5-panel blood test that identifies an autoimmune etiology for patients with dilated cardiomyopathy, myocarditis, atrial fibrillation, and chronic heart failure. The company’s Alzheimer’s Early Intervention Inflammatory Biomarker (AEIIB) program is in development and is anticipated to undergo clinical validation soon.